The analysis was published in a specialization medical journal known as the American Journal of Hematology at 2016.
The Tasigna litigation cases are led toward Novartis both the maker and promoter of this CML therapy medicine. Novartis sought and obtained the acceptance of the U.S. Food and Drug Administration for marketing Tasigna at 2007. Find out more about Tasigna lawyer via http://www.tasignalawsuit.com/tasigna-lawsuit-lawyer.aspx.
Together with other drugs in its own category, Tasigna blocks the creation of a particular protein that basically feeds and enables cancer to develop.
This cardiovascular problem was worthy of a black box warning to the label, but people who have filed a Tasigna lawsuit regularly assert they have experienced rapidly advancing arteriosclerosis-type circulatory problems after beginning to take the CML medication instead.
Within their various Tasigna suit narratives, plaintiffs cite cases where they had been diagnosed with coronary artery to almost complete arterial blockages that were deemed permanent by healthcare professionals.
Based on reports, the CML medication had its label altered by Novartis for its market in Canada as early as 2013. The tag change included the higher arteriosclerosis risk. No attempt was made, but to replace the tag for the U.S. marketplace and healthcare professionals and customers remained ignorant of the potentially fatal side effect.